LQDA (Liquidia) Total Payout Ratio: 0.00 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LQDA Liquidia Corp LQDA
69 GF Score
Price $88.34
GF Value $248.36
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Total Payout Ratio?

Liquidia LQDA +5.40% 69 Total Payout Ratio is 0.00 as of Aug. 04, 2026. GuruFocus rates LQDA with a GF Score™ of 69/100 and a GF Value™ of $248.36 (Possible Value Trap). The stock has 6 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Liquidia's current Total Payout Ratio is 0.00.


Liquidia Total Payout Ratio Related Terms


Liquidia Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Liquidia's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liquidia Total Payout Ratio Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 1.33 0.31 1.08 0.00

Liquidia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LQDA vs LNTH, ALKS, HIMS: Total Payout Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia Total Payout Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liquidia's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Liquidia's Total Payout Ratio falls into.


LQDA
69GF Score
Liquidia Corp LQDA
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liquidia Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Liquidia's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -68.924
=0.00

Liquidia's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / 52.862
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
Liquidia (LQDA) has a Total Payout Ratio of 0.00 as of Aug. 04, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Liquidia and its competitors.
Is Liquidia's Total Payout Ratio too high?
Liquidia's current Total Payout Ratio is 0.00. Overall, Liquidia has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's Total Payout Ratio compare to LNTH and ALKS?
Liquidia's Total Payout Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Drug Manufacturers company?
A good Total Payout Ratio depends on the Drug Manufacturers industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Liquidia and its competitors. Liquidia's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $248.36, compared to a current price of $88.34 — trading 64.4% below its estimated fair value. The current Total Payout Ratio is 0.00. Liquidia's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Liquidia (LQDA), the current Total Payout Ratio is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $88.34 is trading 64.4% below its estimated GF Value™ of $248.36. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Total Payout Ratio: 0.00
  • GF Value™: $248.36 vs. price of $88.34 (64.4% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
69GF Score

Get the complete analysis for LQDA

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$88.34
Price
$248.36
GF Value